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Abstract
Microvascular Function in Metabolically Healthy Groups
Differing in BMI and Waist Circumference
Nathan Earl
Department of Exercise Sciences, BYU
Master of Science
BACKGROUND: Microvascular dysfunction (MD: impaired performance of blood flow, tissue
perfusion, blood pressure, etc.) is one of the earliest stages in the progression of various chronic
diseases. OBJECTIVE: The aim of this study was to determine if a difference in microvascular
function existed between two metabolically healthy groups that differed in BMI and waist
circumference. DESIGN: This study employed a causal comparative design, with two groups: I)
normal weight (n =14, BMI <25 kg/m2), and II) overweight/obese (n = 12, BMI >28 kg/m2).
METHODS: Microvascular function was assessed by measuring skin blood flow (SkBF) using
laser Doppler flowmetry during postocclusive reactive hyperemia (PORH). The area under the
SkBF time curve during the 60-second PORH response was used to quantify the magnitude of
the microvascular response. RESULTS: Group I (control) had a significantly higher average area
under the SkBF time curve (3240 ± 879) than Group II (1948 ± 808) (Z= -3.0094, p = 0.0026).
CONCLUSIONS: The overweight/obese subjects exhibited a diminished skin blood flow
response to occlusion compared to their normal-weight counterparts. This supports the
hypothesis that overweight/obese subjects who are otherwise metabolically healthy exhibit a
biological change that is linked to chronic disease.

Keywords: microvascular dysfunction, abdominal obesity, overweight, obese, metabolically
healthy, metabolic syndrome
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Introduction
The incidence of overweight/obesity is on the rise and is a major concern in the U.S.1-3 It
has reached epidemic proportions and is a major threat to the overall health and well being of
society.4 According to data from the National Health and Nutrition Examination Survey
(NHANES), more than one-third of U.S. adults, over 72 million people, are obese.2,3 Obesity is
related to a number of chronic diseases including hypertension, insulin resistance, type II
diabetes mellitus (T2DM), and coronary heart disease (CHD),5,6 but the underlying mechanisms
of obesity’s contribution remain unclear. Several studies have found that being overweight also
contributes to multiple chronic conditions: gallstones, hypertension, high cholesterol levels,
diabetes, and heart disease.7,8 Exploring the contribution of excess weight to chronic diseases and
identifying its mechanisms of action is crucial to developing effective treatments for
overweight/obesity-related disorders.
Secondary prevention aims to identify biologic changes in asymptomatic people with risk
factors for disease. Overweight/obese people can live for many years without showing symptoms
of chronic disease. Identifying biologic changes before symptoms manifest may not prevent the
onset of disease, but it could detect diseases at an earlier, more treatable stage. One such biologic
change that may exist asymptomatically as a result of obesity is microvascular dysfunction.9
Microvascular dysfunction (MD) is known to be present in T2DM, CHD, metabolic
syndrome, and obesity;9,10 however, its presence is not well established in early stages of those
diseases. The main functions of microcirculation include the regulation of blood flow and tissue
perfusion, blood pressure, tissue fluid (swelling or edema), delivery of oxygen and other
nutrients, removal of CO2 and other metabolic waste products, and body temperature.11 Under
normal conditions, metabolic mechanisms ensure proper regulation of these microcirculatory
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functions. Pathologic conditions such as tissue edema, endothelial disturbance, clogging of
capillaries by neutrophils and microthrombi, and inflammatory free radicals can compromise
these functions and lead to MD.12,13
Studies have shown that MD often accompanies excess weight gain.14-16 Obesityassociated MD is believed to contribute to insulin resistance and hypertension, two leading
causes of T2DM and CHD.9 Some of the symptoms found in obese patients are stunted
vasodilation,17 reduced capillary recruitment,18 and capillary rarefaction.19
One of the most common methods of assessing microvascular function uses laser Doppler
flowmetry (LDF), a noninvasive method of measuring microcirculatory blood flow in tissue.20
Microvascular function is determined by disturbing the normal flow (occlusion or local heat),
then measuring the response (typically in the skin), thus testing the vascular system’s ability to
dilate. Monitoring skin blood flow using laser Doppler flometry (LDF) has been shown to be
both valid and reliable as a means for assessing microvascular function.21
Thus far, research has been focused primarily on overweight/obesity in general, but as far
as we can tell, no studies have compared microvascular function in groups that differ in BMI and
waist circumference but lack any other indicator of metabolic syndrome. While obesity is
generally believed to be dangerous to overall health, current literature lacks clear evidence of the
risks accompanying excess weight gain without associated outward disease states (hypertension,
dyslipidemia, T2DM, CHD, etc.). Examining overweight/obese subjects that are otherwise
healthy offers a unique view of the underlying dangers excess weight gain can cause. Therefore,
the aim of this study was to determine if a difference existed in microvascular function between
two presumably metabolically healthy groups that differed in BMI and waist circumference. To
fulfill this aim, a group of metabolically healthy and normal-weight adults (nonabdominally
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obese; Group I) was compared to a group of overweight/obese adults with abdominal obesity
(Group II). The overweight/obese subjects lacked any other indicator of metabolic syndrome. We
hypothesized that the microvascular function would be attenuated in the overweight/obese but
metabolically healthy group when compared to the normal weight control group.
Methods
Subjects
Volunteers were primarily recruited from the local community and screened, via
telephone, to ensure they met the inclusion criteria. We attempted to match age between the two
groups by finding a counterpart for each subject who was ±3 years. Originally, 30 subjects were
recruited and tested, but four had to be dismissed based on blood test results. Dismissing those
subjects led to a slight imbalance in age matching.
Potential subjects possessing any of the following characteristics were excluded from the
study: adults over the age of 55 years, smokers, individuals taking vasoactive medications (beta
blockers, ACE inhibitors, calcium-channel blockers, diuretics, etc.), postmenopausal women,
women on supplemental estrogen or birth control, pregnant or lactating women, individuals with
diagnosed heart disease or T2DM, and individuals who exercised vigorously more than three
times a week (or >75 total minutes). To estimate physical activity levels, participants were asked
to describe their typical exercise habits in an average week. For each listed activity, the
participants graded their effort levels based on the Borg Rating of Perceived Exertion Scale. The
scale ranges from 6 to 20, where 6 is considered no exertion and 20 is maximal exertion.
Anything above a 14 (rated between “somewhat hard” and “hard” on the Borg scale) was
considered vigorous.22
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BYU’s Institutional Review Board (IRB) approved this study. Prior to participating in the
study, subjects were informed of all potential risks associated with participation and provided
written, informed consent. Study participants were placed into one of two groups based on waist
circumference and BMI. The control group (Group I) consisted of 14 normal-weight individuals
(BMI <25 kg•m-2) without any clinical symptoms associated with metabolic syndrome. The
comparison group (Group II) was comprised of 12 individuals with abdominal obesity (waist
circumference ≥40 inches for men and ≥35 inches for women) and a BMI >28 kg•m-2 but no
clinical symptoms associated with metabolic syndrome.
Waist circumference and blood pressure were determined in the Human Performance
Research Center on Brigham Young University campus. Components of the metabolic syndrome
were determined for participants in each group by a lipid profile and fasting glucose test
performed at a local hospital laboratory (Mount Timpanogos Hospital, Orem, UT). According to
the 2005 International Diabetes Federation definition, metabolic syndrome is present if a patient
has abdominal obesity and at least two of the following four conditions: raised triglyceride levels
(≥150 mg•dL-1), reduced HDL cholesterol (<40 mg•dL-1 in males and <50 mg•dL-1 in females),
raised blood pressure (systolic BP ≥130 or diastolic BP ≥85 mm•Hg-1), and raised fasting plasma
glucose (≥100 mg•dL-1).23 Two female subjects’ HDL levels were 49 mg•dL-1, but we chose to
include them as this falls within the test’s margin of error.
A minimum BMI of 28 kg•m-2 was chosen for Group II because the cut points delineating
BMI categories (normal, overweight, obese) are somewhat arbitrary as risk lies on a continuum.
To increase the likelihood of observing differences between groups, a break in that continuum
was necessary (Group I maximum BMI of 24.99 kg•m-2 and Group II minimum of 28 kg•m-2).
Theoretically, the larger the gap between groups the more likely differences can be detected. We

5
theorized that these cut points would be sufficient to observe a difference in vascular function
between groups while allowing for more manageable subject recruitment.
Study Design
Our study employed a causal comparative design. Independent variables were the criteria
demarcating each group, including: normal weight and no risk factors (Group I) and
overweight/obesity with no other known components of the metabolic syndrome (Group II). The
primary dependent variable of interest was the difference in area under the SkBF time curve
during the 60-second postocclusive reactive hyperemic (PORH) response; however, the five
components of the metabolic syndrome were also compared among groups.
Procedures
In the first appointment, potential subjects completed a participation questionnaire to
confirm that they met all the health and physical activity criteria (< 3 days or 75 minutes of
vigorous activity per week). Next, we measured blood pressure, waist circumference, height, and
weight (to determine BMI). Those subjects who appeared to meet the criteria were sent to a local
hospital laboratory to obtain a blood lipid profile and a fasting blood glucose test. Subjects were
then assigned to their respective groups based on these test results or excluded from the study.
For those who met the criteria, a subsequent appointment was scheduled and completed within a
week of laboratory testing.
In the second appointment we assessed microvascular function using laser Doppler
flowmetry (LDF), a noninvasive method of measuring microcirculatory blood flow in tissue.20
Microvascular function is determined by disturbing the normal flow (occlusion or local heat),
then measuring the payback response of blood flow, thus testing the vascular system’s ability to
dilate.
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Measurements
We used a standard sphygmomanometer and stethoscope to measure blood pressure. To
allow sufficient time for normalization of blood pressure, the first reading was performed after
the subject was in a relaxed sitting position for at least five minutes. We ensured the arm was
supported at heart level and that the hand was relaxed. Measurements were taken until two
consecutive readings differed by no more than 2 mm•Hg-1, with a one-minute lapse between
readings.24
For consistency, we measured waist circumference around the umbilicus, using a flexible,
spring-loaded tape measure. Two measurements were taken, but if the difference was greater
than 2 cm, a third measurement was taken. Measurements were averaged. To accurately
determine subjects’ BMI, height (cm) and weight (kg) were measured to the nearest 0.1 cm and
0.01 kg, respectively, using a stadiometer (Seca, Chino, CA) and weight scale (Tanita, Toyko,
Japan). Subjects wore only spandex shorts or a swimsuit.
To obtain a lipid profile and a fasting blood glucose test, subjects were sent to a local
hospital laboratory. They employ the hexokinase reaction method to determine blood glucose.
For the lipid profile, total cholesterol (TC), high-density lipoproteins (HDL), and triglycerides
(TGL) are measured. Low-density lipoproteins (LDL) are estimated by the Friedewald formula
[Total cholesterol - HDL - (TG/5)], and very-low-density lipoproteins (VLDL) are estimated by
subtracting HDL and LDL from the total cholesterol.25 The lab uses the Dimension Vista
System: Flex reagent cartridge by Siemens to measure HDL, TC, and TGL.
All individuals had to abstain from caffeine-containing drinks for 24 hours prior to their
second appointment, as it is a vasoactive agent.26 The cutaneous microvascular response to
postocclusion reactive hyperemia (PORH) was assessed as an index of microvascular function.
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Skin blood flow (SkBF) was monitored using laser Doppler flowmetry (LDF). Microvascular
measurements were conducted after 30 minutes of acclimatization in a quiet, temperaturecontrolled room (23C), with the measurements obtained from the dorsal aspect of the
nondominant forearm at heart level. SkBF was measured at four skin sites on the upper third of
the anterior forearm on skin without dermatological lesions. Each LDF probe was mounted on
the skin in a thermostatically controlled heater and held at 34°C during the experiment. After
acclimatization to the room temperature we recorded baseline SkBF for 15 minutes. Next, a cuff
around the upper arm was inflated to 200 mmHg for 5 minutes. The cuff was rapidly deflated
and the PORH response was monitored for 10 minutes.27,28
Following PORH, the four skin sites were heated to 44C for 30 minutes to produce a
peak cutaneous vasodilation. We used the peak dilation during local heating to normalize all skin
blood flow readings and express the data as a percentage of the peak vasodilation rather than a
percentage of baselines.28
Data Analysis
PC-SAS (version 9.3, SAS Institute, Inc., Cary, NC) was used to analyze all data. Alpha
level was set at p < 0.05 for all statistical tests. Descriptive data was summarized with means and
standard deviations. Area under the SkBF time curve (AUC) was calculated using the GraphPad
Prism 6 software program (San Diego, CA). This program employs the “trapezoidal rule” to find
the area under the SkBF time curve, where each small trapezoid within the area is computed and
then the total sum of those smaller trapezoids equals the total AUC. The AUC calculation was
applied to the 60-second PORH response using normalized SkBF reported as a percentage of
peak flow. All four SkBF channels were analyzed and then averaged to yield a single number for
each subject. The individual subjects were then averaged for each group and analyzed for
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differences between groups. Group differences regarding basic characteristics and metabolic
syndrome criteria were determined using the General Linear Model. Area under the SkBF time
curve was analyzed for normality within each group using the NPAR1WAY procedure in SAS.
This procedure yields several different tests for normality (e.g., Shapiro-Wilk). As the data were
not normally distributed, differences in the experimental outcome (area under the SkBF time
curve) were analyzed using the nonparametric Wilcoxon-Mann-Whitney test. This test compares
independent samples and is the equivalent of a t-test for normally distributed data. Age, a
potentially confounding variable, was also shown to be nonnormally distributed using the
NPAR1WAY procedure. However, the Wilcoxon-Mann-Whitney test for age did not reveal a
difference; thus, was not used as a covariate in the analysis.
Results
Table 1 includes basic group characteristics. Means between the two groups differed
significantly in weight (p = 0.0003) and BMI (p < 0.0001), but not in height or age (p > 0.65). It
also shows statistics for metabolic syndrome criteria and group values. Mean differences
between groups were significant for waist circumference (p < 0.0001), but not for any other
component of the metabolic syndrome.
The main outcome of interest in this study was the SkBF response to PORH. The area
under the SkBF time curve for 60 seconds after the release of the blood pressure cuff averaged
3239 ± 879 SkBF %peak • sec for Group I, while Group II averaged 1948 ± 808 SkBF %peak • sec
(Z = -3.0094, p = 0.0026). Age was examined with the Wilcoxon-Mann-Whitney test to find a
potential difference between groups, but it was not significant (p = 0.3790). A very large effect
size of group means for area under the SkBF time curve was also found (Cohen’s d effect size =
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1.53; SE = 0.3). Neither baseline nor peak heat values were significantly different between
groups.
Discussion
The objective of this study was to determine if a difference existed in microvascular
function between two metabolically healthy groups that differed in BMI and waist
circumference. We observed a significant difference in the SkBF response to PORH. In support
of our hypothesis, it appears that overweight/obese subjects without compounding risk factors
for metabolic syndrome exhibit reduced microvascular function. The reduction in the SkBF
response during PORH reflects some degree of MD in this group. In addition, the large effect
size suggests a strong ability to detect a difference between groups for the SkBF response to
PORH. Seeing a difference in microvascular function between the two groups despite the small
sample size is evidence that the effect of excess weight on microvascular function is fairly
strong. This offers some unique support that underlying biological changes exist in overweight/
obese subjects despite a lack of outward disease states.
Though our design attempted to control for age by matching, there was a wide range of
ages among subjects (18–51). To ensure age did not modify the difference between groups in
SkBF response to PORH, we applied the Wilcoxon-Mann-Whitney test to the age data. Since it
was not significant, we assume that age did not significantly contribute to the difference we saw
in SkBF response.
If we look at the present study in the context of previous studies, it’s apparent that
overweight/obesity may impair microvascular function in several ways. As noted by de Jongh et
al., overweight/obese subjects exhibited stunted vasodilation in response to common
endothelium-dependent vasodilators in skin and resistance arteries.17 Additionally, Arcaro et al.

10
showed reduced vasodilator function of resistance vessels and capillary recruitment in response
to reactive hyperemia and shear stress among obese subjects.18 As evidenced by the difference in
area under the SkBF time curve between the groups in our study, those with elevated BMI’s and
abdominal obesity also exhibited a similar reduction in vasodilator function in response to
reactive hyperemia.
Beyond these functional changes, multiple studies observed structural damages of the
microvasculature. Frisbee et al. found that skeletal muscle circulation of obese Zucker rats
exhibits decreased capillary density (rarefaction) and structural remodeling.29,30 Recently, a
human study of obese individuals (with and without metabolic syndrome) found a negative
correlation of skin capillary density with waist circumference and BMI.19 As BMI and waist
circumference increased, capillary density decreased. While our study did not directly examine
structural components of microvasculature, it is possible that rarefaction and structural
remodeling may at least partially explain the difference in the PORH response between the two
groups. Since there was no significant difference between the two groups in regards to peak
heated values, it seems that obesity does not affect all vasodilator mechanisms equally. Reactive
hyperemic mechanisms were certainly impaired in the overweight/obese group versus the control
group. However, the mechanisms regulating heated dilation were not measurably different
between obese and nonobese subjects.
While other studies link obesity with MD,12,17,18 there is a gap in the research where
otherwise metabolically healthy overweight/obese subjects are concerned. Our study was a step
in exploring one of many underlying biological changes brought on by excess weight gain.
Further exploration of this relationship would prove beneficial to understanding one of the many
complications obesity produces.
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There is great potential to advance future research in this area. A more varied racial
makeup would be more representative of the general population. A third group with advanced
stages of chronic disease (T2DM or CHD) could also be added since MD is well documented in
these disease states. Such a group would provide another reference point to compare the PORH
responses between groups. Overweight/obese subjects who exhibit dysfunction could also be
followed over time to monitor any deterioration of vascular function along with progression of
chronic diseases. Randomized control trials could also be conducted to evaluate and quantify the
effect of various interventions (weight loss, exercise programs, drug therapy, etc.) on vascular
function.
Our study had a few limitations. As in correlational studies, a causal-comparative study
can identify relationships, but it does not establish causation. Randomized control trials are
necessary to establish a temporal cause and effect relationship. The racial makeup of our study
(85% Caucasian) decreased the ability to generalize to the population as a whole. During the
recruiting stages, participants were asked to describe their typical physical activity habits to
ensure they met the criteria. Misrepresentation, intentional or not, is certainly a possibility.
Exercise training can improve vascular function, independent of any weight loss,31 and is thus a
potential confounding variable in this study.
Conclusion
A reduction in microvascular function is one of the earliest physiological changes
observed prior to overt clinical symptoms of various chronic diseases (hypertension,
dyslipidemia, T2DM, CVD, etc.). Determining the conditions that initiate microcirculatory
dysfunction would be crucial to understanding the progression of many chronic diseases.
Overweight and obesity as a whole is connected to various chronic conditions, MD being one of
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them. The subjects in our study with elevated BMI’s and waist circumferences exhibited a
diminished skin blood flow response to occlusion compared to their normal-weight counterparts.
This demonstrates that overweight/obese subjects who are otherwise metabolically healthy
exhibit a biological change that is associated with several chronic diseases and appears to be an
early biomarker for disease progression. This is an important step in understanding one of many
underlying complications caused by excess weight.
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Table 1: Group Characteristics and Criteria Variables Associated with Metabolic Syndrome
Variable

Group I (n = 14)

Group II (n = 12)

Age

27.93 ± 9.98

29.75 ± 10.38

Weight (kg)

65.41 ± 11.13

91.77 ± 14.32*

Height (cm)

172.63 ± 9.25

173.08 ± 10.80

BMI (kg•m-2)

21.85 ± 1.99

30.41 ± 1.39*

Waist Circ (cm)

78.15 ± 5.68

102.95 ± 5.25*

SBP (mm•Hg-1)

113 ± 7

114 ± 6

DBP (mm•Hg-1)

73 ± 7

73 ± 6

Glucose (mg•dL-1)

88.3 ± 6.8

88.0 ± 8.9

TC (mg•dL-1)

158 ± 18

170 ± 17

LDL (mg•dL-1)

92 ± 20

108 ± 20

HDL (mg•dL-1)

52 ± 7

47 ± 4

TG (mg•dL-1)

96 ± 24

114 ± 17

Values represent mean ± 1 SD
BMI: Body mass index; Circ: circumference; SBP: Systolic Blood Pressure; DBP: Diastolic
Blood Pressure; Glucose: fasting blood glucose; TC: Total cholesterol; LDL: Low-Density
Lipoproteins; HDL: High-Density Lipoproteins; TG: Triglycerides.
*p < 0.05 Group II (overweight/obese) different from Group I (control).
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Table 2: Microvascular Function Analysis
Mean
(Group I, n = 14)

Mean
(Group II, n = 12)

p

Baseline (V)

0.28 ± 0.07

0.24 ± 0.04

0.1127

Peak Heat (V)

1.72 ± 0.53

1.65 ± 0.74

0.6251

AUC (SkBF %peak • sec )

3239 ± 879

1948 ± 808

0.0026

Variable

Values represent mean ± 1 SD
(V): volts; AUC: area under the SkBF time curve analysis

